These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 23258807)

  • 1. Prevalence of microalbuminuria in type 2 diabetes: lessons learned from the ROADMAP study.
    Ritz E; Menne J; Haller H
    Nephrol Dial Transplant; 2012 Dec; 27 Suppl 4():iv28-30. PubMed ID: 23258807
    [No Abstract]   [Full Text] [Related]  

  • 2. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
    Chatzikyrkou C; Menne J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1087-92. PubMed ID: 23098143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H; Viberti GC; Mimran A; Remuzzi G; Rabelink AJ; Ritz E; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Januszewicz A
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
    Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
    Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
    [No Abstract]   [Full Text] [Related]  

  • 5. Office and ambulatory pulse pressure--association with clinical characteristics and cardiovascular risk factors in normoalbuminuric patients with type 2 diabetes (ROADMAP study).
    Januszewicz A; Ritz E; Viberti G; Mimran A; Rabelink AJ; Rump LC; Ruilope LM; Katayama S; Ito S; Izzo JL; Haller H
    J Hum Hypertens; 2011 Nov; 25(11):679-85. PubMed ID: 21150933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetes: ROADMAP: the road to renoprotection?
    Roscioni SS; Heerspink HJ; de Zeeuw D
    Nat Rev Nephrol; 2011 May; 7(8):427-8. PubMed ID: 21610679
    [No Abstract]   [Full Text] [Related]  

  • 7. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR
    N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
    [No Abstract]   [Full Text] [Related]  

  • 8. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) observational follow-up study: benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation.
    Menne J; Ritz E; Ruilope LM; Chatzikyrkou C; Viberti G; Haller H
    J Am Heart Assoc; 2014; 3(2):e000810. PubMed ID: 24772521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gender on transition of normo- to microalbuminuria under angiotensin receptor blocker therapy in diabetes.
    Scurt FG; Menne JJ; Korda A; Haller H; Chatzikyrkou C
    J Diabetes; 2020 Nov; 12(11):856-859. PubMed ID: 32755046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Primary cardiorenal prevention in patients with type-2 diabetes. The Roadmap study].
    Halimi S
    Presse Med; 2005 Oct; 34(18):1300-2. PubMed ID: 16269993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes.
    Estacio RO; Coll JR; Tran ZV; Schrier RW
    Am J Hypertens; 2006 Dec; 19(12):1241-8. PubMed ID: 17161769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
    Ruilope L; Izzo J; Haller H; Waeber B; Oparil S; Weber M; Bakris G; Sowers J
    J Clin Hypertens (Greenwich); 2010 Jun; 12(6):422-30. PubMed ID: 20591087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized Olmesartan And Diabetes Microalbuminuria Prevention Study (ROADMAP).
    Ritz E
    Pol Arch Med Wewn; 2011 May; 121(5):145-7. PubMed ID: 21610661
    [No Abstract]   [Full Text] [Related]  

  • 15. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial.
    Agha A; Amer W; Anwar E; Bashir K
    Saudi J Kidney Dis Transpl; 2009 May; 20(3):429-35. PubMed ID: 19414946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "ROADMAP" controversies.
    Cohen DL; Townsend RR
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):628. PubMed ID: 21806774
    [No Abstract]   [Full Text] [Related]  

  • 17. Olmesartan, microalbuminuria, and type 2 diabetes.
    Fioretto P; Mauer M
    N Engl J Med; 2011 Jun; 364(23):2260-1; author reply 2262-3. PubMed ID: 21651400
    [No Abstract]   [Full Text] [Related]  

  • 18. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Type 2 diabetic patient with kidney damage. Sartans banish dialysis risk].
    MMW Fortschr Med; 2004 Jul; 146(27-28):56. PubMed ID: 15526676
    [No Abstract]   [Full Text] [Related]  

  • 20. Olmesartan, microalbuminuria, and type 2 diabetes.
    Yudkin JS; Lehman R
    N Engl J Med; 2011 Jun; 364(23):2260; author reply 2262-3. PubMed ID: 21651401
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.